Kadmon Corporation, LLC

Heidi Krenz

David Eiznhamer

The present disclosure provides methods of administering belumosudil mesylate salt to patients with chronic graft-versus-host disease (cGVHD), wherein the methods include identifying adverse reactions in the patients, such as an infection, and modifying the administration based on the results of such identification, such as by ceasing administration when the infection is a Grade 3 or Grade 4 level infection.

Growing community of inventors

Cambridge, MA, United States of America

Heidi Krenz